Identification of Novel Activators of Constitutive Androstane Receptor from FDA-Approved Drugs by Integrated Computational and Biological Approaches

Caitlin Lynch,Yongmei Pan,Linhao Li,Stephen S. Ferguson,Menghang Xia,Peter W. Swaan,Hongbing Wang
DOI: https://doi.org/10.1007/s11095-012-0895-1
2011-01-01
The FASEB Journal
Abstract:The nuclear receptor CAR is a well established xenobiotic sensor governing the transcription of numerous hepatic genes associated with xenobiotic metabolism and clearance. Recent evidence suggests that mouse CAR also functions as a mediator of energy metabolism and cancer development. However, whether its human counterpart holds these novel functionsis largely unknown due to the lack of selective human (h) CAR modulators. Here, we have identified several novel hCAR activators by applying 1) virtual screening of chemical databases with ligand‐based structure‐activity models; and 2) cell‐based assays that proved to be efficient in the determination of hCAR activation. Initial screening of the CDD drug database using structure‐activity models and docking has resulted in 20 lead compounds with optimal pharmacophore parameters. In cell‐based reporter assays, two of the 20 leads exhibited robust activation of hCAR. In human primary hepatocyte cultures, these two compounds efficiently translocated hCAR from cytoplasm to nucleus, which has been recognized as the initial step of CAR activation. Moreover, these compounds also induced the expression of the prototypical hCAR target genes, CYP2B6 and CYP3A4. These results clearly indicate that our combined strategy is efficient in the identification of novel hCAR modulators. This work was partly supported by NIH Grant (DK061652).
What problem does this paper attempt to address?